Oncology drug development: United States Food and Drug Administration perspective.
about
Rexin-G, a targeted genetic medicine for cancer.Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm.Development and use of biomarkers in oncology drug development.Oncology drug development and approval of systemic anticancer therapy by the U.S. Food and Drug AdministrationAcceptance of surrogate end points in clinical trials supporting approval of drugs for cancer treatment by the Japanese regulatory agency.Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs.
P2860
Oncology drug development: United States Food and Drug Administration perspective.
description
2002 nî lūn-bûn
@nan
2002 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Oncology drug development: United States Food and Drug Administration perspective.
@ast
Oncology drug development: United States Food and Drug Administration perspective.
@en
Oncology drug development: United States Food and Drug Administration perspective.
@nl
type
label
Oncology drug development: United States Food and Drug Administration perspective.
@ast
Oncology drug development: United States Food and Drug Administration perspective.
@en
Oncology drug development: United States Food and Drug Administration perspective.
@nl
prefLabel
Oncology drug development: United States Food and Drug Administration perspective.
@ast
Oncology drug development: United States Food and Drug Administration perspective.
@en
Oncology drug development: United States Food and Drug Administration perspective.
@nl
P1476
Oncology drug development: United States Food and Drug Administration perspective.
@en
P2093
Richard Pazdur
Steven Hirschfeld
P304
P356
10.1016/S1040-8428(02)00008-2
P577
2002-05-01T00:00:00Z